(Q38254295)

1 September 2017

1 reference

title

Advances in pharmacotherapy of small cell lung cancer (English)

1 reference

1 September 2017

0 references

1 reference

Gregory P. Kalemkerian

series ordinal

1

object named as

Gregory P Kalemkerian

1 reference

1 September 2017

language of work or name

English

0 references

publication date

26 September 2014

1 reference

Expert Opinion on Pharmacotherapy

1 September 2017

published in

1 reference

1 September 2017

volume

15

1 reference

1 September 2017

issue

16

1 reference

1 September 2017

page(s)

2385-2396

1 reference

Cigarette smoking and lung cancer--relative risk estimates for the major histological types from a pooled analysis of case-control studies

1 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

21 January 2018

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung ca

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

A meta-analysis of thoracic radiotherapy for small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

Prophylactic cranial irradiation in extensive small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

Small-cell lung cancer: state of the art.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

The superiority of combination chemotherapy over single agent chemotherapy in small cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

Chemotherapy of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

Randomized Trial of Cyclophosphamide, Doxorubicin, and Vincristine Versus Cisplatin and Etoposide Versus Alternation of These Regimens in Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 s

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

Topotecan/cisplatin compared with cisplatin/etoposide as first-line treatment for patients with extensive disease small-cell lung cancer: final results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

Camptothecins compared with etoposide in combination with platinum analog in extensive stage small cell lung cancer: systematic review with meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

Phase II trial of paclitaxel and carboplatin in metastatic small-cell lung cancer: a Groupe Français de Pneumo-Cancérologie study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

Novel doublets in extensive-stage small-cell lung cancer: a randomized phase II study of topotecan plus cisplatin or paclitaxel (CALGB 9430).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

Maintenance or consolidation therapy in small-cell lung cancer: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer: JCOG 0509.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

Evaluation of the recommended dose and efficacy of amrubicin as second- and third-line chemotherapy for small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

Retrospective analysis of efficacy and safety of amrubicin in refractory and relapsed small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

A framework for identification of actionable cancer genome dependencies in small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the Europea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

A phase II study of all-trans-retinoic acid plus cisplatin and etoposide in patients with extensive stage small cell lung carcinoma: an Eastern Cooperative Oncology Group Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

Phase II trial of fenretinide (NSC 374551) in patients with recurrent small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

Clinical Significance and Molecular Characteristics of Circulating Tumor Cells and Circulating Tumor Microemboli in Patients With Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.957180

10.1517/14656566.2014.957180

21 January 2018

Identifiers

DOI

1 reference

1 September 2017

1 reference